RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
    3.
    发明申请
    RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders 审中-公开
    RNAi介导的RHO激酶抑制治疗眼部疾病

    公开(公告)号:US20070149473A1

    公开(公告)日:2007-06-28

    申请号:US11641410

    申请日:2006-12-19

    IPC分类号: A61K48/00

    摘要: RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2.

    摘要翻译: 提供了用于抑制Rho激酶mRNA表达以治疗眼部疾病患者的RNA干扰,特别是用于治疗眼内压,眼高压和青光眼。 Rho激酶mRNA靶标包括ROCK1和ROCK2的mRNA。

    RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS
    4.
    发明申请
    RNAi-MEDIATED INHIBITION OF IGF1R FOR TREATMENT OF OCULAR ANGIOGENESIS 审中-公开
    IGF1R的RNAi介导的抑制作用以治疗血栓形成

    公开(公告)号:US20070275922A1

    公开(公告)日:2007-11-29

    申请号:US11617899

    申请日:2006-12-29

    IPC分类号: A61K31/7105 A61P7/00

    摘要: RNA interference is provided for inhibition of IGF1R mRNA expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (PSNV), and neovascular glaucoma, and for treating patients at risk of developing such conditions.

    摘要翻译: 提供RNA干扰用于治疗患有眼血管生成的患者的IGF1R mRNA表达,特别是用于治疗视网膜水肿,糖尿病性视网膜病变,与视网膜缺血相关的后遗症,后段新生血管形成(PSNV)和新生血管性青光眼,并用于治疗患有风险的患者 发展这样的条件。

    RNAi-mediated inhibition of ocular hypertension targets
    9.
    发明申请
    RNAi-mediated inhibition of ocular hypertension targets 审中-公开
    RNAi介导的高眼压症目标抑制

    公开(公告)号:US20060172963A1

    公开(公告)日:2006-08-03

    申请号:US11344702

    申请日:2006-02-01

    IPC分类号: A61K48/00

    摘要: RNA interference is provided for inhibition of ocular hypertension target mRNA expression for lowering elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Ocular hypertension targets include carbonic anhydrase II, IV, and XII; β1- and β2 adrenergic receptors; acetylcholinesterase; Na+/K+-ATPase; and Na—K-2Cl cotransporter. Ocular hypertension is treated by administering interfering RNAs of the present invention.

    摘要翻译: 提供RNA干扰用于抑制眼高血压靶mRNA表达,以降低开角型青光眼或高眼压患者眼内压升高。 眼睛高血压指标包括碳酸酐酶II,IV和XII; β1-和β2肾上腺素能受体; 乙酰胆碱酯酶; Na + + / K + + -ATP酶; 和Na-K-2Cl共转运蛋白。 通过施用本发明的干扰RNA来治疗眼高血压。